Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Shattuck Labs Inc (STTK)

Shattuck Labs Inc (STTK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 498,334
  • Shares Outstanding, K 47,551
  • Annual Sales, $ 1,660 K
  • Annual Income, $ -87,300 K
  • 60-Month Beta 2.11
  • Price/Sales 314.81
  • Price/Cash Flow N/A
  • Price/Book 3.11
Trade STTK with:

Options Overview Details

View History
  • Implied Volatility 155.23% ( -11.19%)
  • Historical Volatility 74.29%
  • IV Percentile 76%
  • IV Rank 13.86%
  • IV High 870.89% on 10/17/23
  • IV Low 40.03% on 06/15/23
  • Put/Call Vol Ratio 7.00
  • Today's Volume 32
  • Volume Avg (30-Day) 124
  • Put/Call OI Ratio 0.72
  • Today's Open Interest 2,776
  • Open Int (30-Day) 3,323

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.47
  • Number of Estimates 2
  • High Estimate -0.43
  • Low Estimate -0.50
  • Prior Year -0.49
  • Growth Rate Est. (year over year) +4.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.55 +27.02%
on 04/02/24
11.58 -6.22%
on 04/29/24
+1.97 (+22.16%)
since 04/01/24
3-Month
8.06 +34.74%
on 03/19/24
11.58 -6.22%
on 04/29/24
+1.36 (+14.32%)
since 02/01/24
52-Week
1.33 +716.48%
on 10/06/23
11.58 -6.22%
on 04/29/24
+7.78 (+252.60%)
since 05/01/23

Most Recent Stories

More News
Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Misses Revenue Estimates

Shattuck Labs, Inc. (STTK) delivered earnings and revenue surprises of 19.67% and 83.24%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

STTK : 10.86 (+3.63%)
CELU : 3.02 (-0.33%)
Shattuck Labs, Inc. (STTK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Shattuck Labs, Inc. (STTK), indicating that the stock has found support. This, combined with an upward trend in earnings estimate...

STTK : 10.86 (+3.63%)
Shattuck Labs Reports Second Quarter 2022 Financial Results and Recent Business Highlights

– Enrollment of Phase 1B clinical trial of SL-172154 in combination with liposomal doxorubicin in platinum-resistant ovarian cancer expected to begin in...

STTK : 10.86 (+3.63%)
Should You Buy Shattuck Labs (STTK) Ahead of Earnings?

Shattuck Labs (STTK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

STTK : 10.86 (+3.63%)
Shattuck Labs Reports First Quarter 2022 Financial Results and Recent Business Highlights

– Dose escalation ongoing in Phase 1 clinical trial of SL-172154 in platinum-resistant ovarian cancer; combination trial with liposomal doxorubicin on...

STTK : 10.86 (+3.63%)
Why Earnings Season Could Be Great for Shattuck Labs (STTK)

Shattuck Labs (STTK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

STTK : 10.86 (+3.63%)
Shattuck Labs Presents Preclinical Data at the 2022 American Association for Cancer Research (AACR) Annual Meeting

- SL-9258 (TIGIT-Fc-LIGHT) combined with anti-PD(L)1 broadened anti-tumor activity of the checkpoint antibodies in aggressive CPI-resistant tumors - -...

STTK : 10.86 (+3.63%)
Shattuck Labs Announces Participation in Upcoming 21st Annual Needham Virtual Healthcare Conference

AUSTIN, TX and DURHAM, NC, April 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the...

STTK : 10.86 (+3.63%)
SHATTUCK ALERT: Bragar Eagel & Squire, P.C. is Investigating Shattuck Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Shattuck Labs, Inc. (NASDAQ: STTK) on behalf of long-term stockholders following...

STTK : 10.86 (+3.63%)
STTK Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Shattuck Labs, Inc. Investors of Last Few Hours to Actively Participate in the Class Action

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ: STTK) and certain...

STTK : 10.86 (+3.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Shattuck Labs Inc. is a clinical-stage biotechnology company. It engages in development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease. The company's wholly owned program includes SL-172154. It operates principally in Durham, North...

See More

Key Turning Points

3rd Resistance Point 12.37
2nd Resistance Point 11.82
1st Resistance Point 11.34
Last Price 10.86
1st Support Level 10.31
2nd Support Level 9.76
3rd Support Level 9.28

See More

52-Week High 11.58
Last Price 10.86
Fibonacci 61.8% 7.66
Fibonacci 50% 6.46
Fibonacci 38.2% 5.25
52-Week Low 1.33

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar